Rare Case of Endoscopic Treatment for Bevacizumab-Related Gastric Perforation in a Patient with Ovarian Cancer

被引：1
|
作者：
Cappuccio, Serena [1 ]
Marinucci, Benito [2 ]
Bove, Vincenzo [3 ]
Turco, Luigi Carlo [4 ,5 ]
Cosentino, Francesco [5 ]
Scambia, Giovanni [1 ,2 ]
Costamagna, Guido [2 ,3 ]
Boskoski, Ivo [2 ,3 ]
机构：
[1] Fdn Policlin Univ A Gemelli IRCCS, Dept Womans Childs & Publ Hlth, Rome, Italy
[2] Univ Cattolica Sacro Cuore, Fac Med & Chirurg, Rome, Italy
[3] Fdn Policlin Univ Agostino Gemelli IRCCS, Digest Endoscopy Unit, Rome, Italy
[4] Mater Olbia Spa, Gynecol & Breast Care Unit, Olbia, Italy
[5] Univ Cattolica Sacro Cuore, Gynecol Oncol, Gemelli Molise Spa, Campobasso, Italy
来源：
CHEMOTHERAPY | 2020年 / 65卷 / 1-2期
关键词：
Adverse events; Bevacizumab; Endoscopic suture; Gastric perforation; Ovarian cancer; GASTROINTESTINAL PERFORATION; PHASE-3; TRIAL; CHEMOTHERAPY; THERAPY; RISK; COMBINATION; FOCUS;
D O I：
10.1159/000508556
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Antiangiogenic chemotherapy is a common treatment option for patients with advanced ovarian cancer (OC) and has been proven to be effective and generally safe. Nevertheless, in rare cases, these drugs can give serious complications such as gastrointestinal perforations that can be even mortal or very difficult to treat and can heavily impact the clinical management. We present a rare case of bevacizumab-induced gastric perforation in a patient with advanced OC occurred during bevacizumab-including chemotherapy in an adjuvant setting. Surgical treatment was not possible due to the frailty of the clinical condition of the patient and the gastric perforation was successfully treated with endoscopic suturing.
引用
收藏
页码：54 / 57
页数：4
相关论文
共 50 条
  • [41] A Case Report of Gastrointestinal Hemorrhage and Perforation During Apatinib Treatment of Gastric Cancer
    Li, Xiao-Fen
    Tan, Yi-Nuo
    Cao, Ying
    Xu, Jing-Hong
    Zheng, Shu
    Yuan, Ying
    MEDICINE, 2015, 94 (39) : e1661
  • [42] Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: A case report and review of the literature
    Fujii Y.
    Hirahara N.
    Kaji S.
    Taniura T.
    Hyakudomi R.
    Yamamoto T.
    Tajima Y.
    Journal of Medical Case Reports, 12 (1)
  • [43] Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma
    Lallemand, Christophe
    Ferrando-Miguel, Rosa
    Auer, Michael
    Iglseder, Sarah
    Czech, Theresa
    Gaber-Wagener, Anouk
    Di Pauli, Franziska
    Deisenhammer, Florian
    Tovey, Michael G.
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [44] The cost-effectiveness of bevacizumab for the treatment of advanced ovarian cancer in Canada
    Duong, M.
    Wright, E.
    Yin, L.
    Martin-Nunez, I.
    Ghatage, P.
    Fung-Kee-Fung, M.
    CURRENT ONCOLOGY, 2016, 23 (05) : E461 - E467
  • [45] Ovarian cancer with breast metastasis: a rare case report
    Dang, Tien Giang
    Nguyen, Hong Quang
    Khuc, Chi Hieu
    Tran, Trung Toan
    Nguyen, Thanh Long
    ANNALS OF MEDICINE AND SURGERY, 2025, 87 (01): : 393 - 397
  • [46] A Very Rare Reason for Gastric Perforation, Caused by Gastric Metastasis of Breast Cancer: Case Presentation
    Guler, Sertac Ata
    Simsek, Turgay
    Posteki, Gokhan
    Guresin, Alican
    Cinar, Saffet
    Onbasilar, Umut
    Canturk, Nuh Zafer
    EUROPEAN JOURNAL OF BREAST HEALTH, 2019, 15 (01) : 59 - 62
  • [47] Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: A Gynecologic Oncology Group Study
    Monk, Bradley J.
    Huang, Helen Q.
    Burger, Robert A.
    Mannel, Robert S.
    Homesley, Howard D.
    Fowler, Jeffrey
    Greer, Benjamin E.
    Boente, Matthew
    Liang, Sharon X.
    Wenzel, Lari
    GYNECOLOGIC ONCOLOGY, 2013, 128 (03) : 573 - 578
  • [48] Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment
    Havrilesky, Laura J.
    Lim, Stephanie
    Ehrisman, Jessie A.
    Lorenzo, Amelia
    Secord, Angeles Alvarez
    Yang, Jui-Chen
    Johnson, F. Reed
    Gonzalez, Juan Marcos
    Reed, Shelby D.
    GYNECOLOGIC ONCOLOGY, 2020, 156 (03) : 561 - 567
  • [49] Incidence of gastrointestinal perforation associated with bevacizumab in combination with neoadjuvant chemotherapy as first- line treatment of advanced ovarian, fallopian tube, or peritoneal cancer: analysis of a Japanese healthcare claims database
    Ueda, Akihiko
    Watari, Hidemichi
    Mandai, Masaki
    Fukuhara, Shunichi
    Sugitani, Yasuo
    Ogino, Kiyoko
    Kamijima, Shuichi
    Enomoto, Takayuki
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2022, 33 (06)
  • [50] Efficacy of bevacizumab combined with apatinib in the treatment of advanced metastatic gastric cancer
    Yu, Chunmei
    Zhuang, Wei
    Miao, Qiangqiang
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2024, 16 (08): : 4032 - 4041
12345